San Diego, CA based pharma company Ligand is buying Pharmacopeia for about $70 Million in a deal that involves $55 million in stock, plus $15 million tied to the DARA program, Pharmacopeia's lead internal development candidate (PS433540) for hypertension, licensed from Bristol-Myers Squibb Co.